These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1452 related articles for article (PubMed ID: 25999370)

  • 1. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.
    Winter GE; Buckley DL; Paulk J; Roberts JM; Souza A; Dhe-Paganon S; Bradner JE
    Science; 2015 Jun; 348(6241):1376-81. PubMed ID: 25999370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
    Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
    J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
    Lu J; Qian Y; Altieri M; Dong H; Wang J; Raina K; Hines J; Winkler JD; Crew AP; Coleman K; Crews CM
    Chem Biol; 2015 Jun; 22(6):755-63. PubMed ID: 26051217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer drugs: Selectively targeting proteins for degradation.
    Crunkhorn S
    Nat Rev Drug Discov; 2015 Jul; 14(7):459. PubMed ID: 26091269
    [No Abstract]   [Full Text] [Related]  

  • 5. Phthalimide-Conjugated Ligands Promote Selective Protein Destabilization.
    Cancer Discov; 2015 Jul; 5(7):691. PubMed ID: 26045013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
    Saenz DT; Fiskus W; Qian Y; Manshouri T; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Mill CP; Sun B; Qiu P; Kadia TM; Pemmaraju N; DiNardo C; Kim MS; Nowak AJ; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
    Leukemia; 2017 Sep; 31(9):1951-1961. PubMed ID: 28042144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasticity in binding confers selectivity in ligand-induced protein degradation.
    Nowak RP; DeAngelo SL; Buckley D; He Z; Donovan KA; An J; Safaee N; Jedrychowski MP; Ponthier CM; Ishoey M; Zhang T; Mancias JD; Gray NS; Bradner JE; Fischer ES
    Nat Chem Biol; 2018 Jul; 14(7):706-714. PubMed ID: 29892083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and characterization of bivalent BET inhibitors.
    Tanaka M; Roberts JM; Seo HS; Souza A; Paulk J; Scott TG; DeAngelo SL; Dhe-Paganon S; Bradner JE
    Nat Chem Biol; 2016 Dec; 12(12):1089-1096. PubMed ID: 27775715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
    Otto C; Schmidt S; Kastner C; Denk S; Kettler J; Müller N; Germer CT; Wolf E; Gallant P; Wiegering A
    Neoplasia; 2019 Nov; 21(11):1110-1120. PubMed ID: 31734632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation.
    Nie X; Zhao Y; Tang H; Zhang Z; Liao J; Almodovar-Rivera CM; Sundaresan R; Xie H; Guo L; Wang B; Guan H; Xing Y; Tang W
    Chembiochem; 2024 Feb; 25(4):e202300685. PubMed ID: 38116854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROTAC-mediated crosstalk between E3 ligases.
    Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
    Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective degradation of BET proteins with dBET1, a proteolysis-targeting chimera, potently reduces pro-inflammatory responses in lipopolysaccharide-activated microglia.
    DeMars KM; Yang C; Castro-Rivera CI; Candelario-Jalil E
    Biochem Biophys Res Commun; 2018 Feb; 497(1):410-415. PubMed ID: 29448097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway.
    Ottis P; Palladino C; Thienger P; Britschgi A; Heichinger C; Berrera M; Julien-Laferriere A; Roudnicky F; Kam-Thong T; Bischoff JR; Martoglio B; Pettazzoni P
    ACS Chem Biol; 2019 Oct; 14(10):2215-2223. PubMed ID: 31553577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma.
    He L; Chen C; Gao G; Xu K; Ma Z
    Aging (Albany NY); 2020 Mar; 12(5):4547-4557. PubMed ID: 32163373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homo-PROTACs for the Chemical Knockdown of Cereblon.
    Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
    ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications.
    Ward CC; Kleinman JI; Brittain SM; Lee PS; Chung CYS; Kim K; Petri Y; Thomas JR; Tallarico JA; McKenna JM; Schirle M; Nomura DK
    ACS Chem Biol; 2019 Nov; 14(11):2430-2440. PubMed ID: 31059647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
    Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP
    Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis of PROTAC cooperative recognition for selective protein degradation.
    Gadd MS; Testa A; Lucas X; Chan KH; Chen W; Lamont DJ; Zengerle M; Ciulli A
    Nat Chem Biol; 2017 May; 13(5):514-521. PubMed ID: 28288108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER).
    Ohoka N; Ujikawa O; Shimokawa K; Sameshima T; Shibata N; Hattori T; Nara H; Cho N; Naito M
    Chem Pharm Bull (Tokyo); 2019 Mar; 67(3):203-209. PubMed ID: 30369550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent and selective bivalent inhibitors of BET bromodomains.
    Waring MJ; Chen H; Rabow AA; Walker G; Bobby R; Boiko S; Bradbury RH; Callis R; Clark E; Dale I; Daniels DL; Dulak A; Flavell L; Holdgate G; Jowitt TA; Kikhney A; McAlister M; Méndez J; Ogg D; Patel J; Petteruti P; Robb GR; Robers MB; Saif S; Stratton N; Svergun DI; Wang W; Whittaker D; Wilson DM; Yao Y
    Nat Chem Biol; 2016 Dec; 12(12):1097-1104. PubMed ID: 27775716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.